Phosphine

Phosphine

SCHEMBL6665557

P.c1ccc2c(-c3cccc4ccccc34)cccc2c1

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.56
HSD17B10 Q99714 7/20 0.56
TSHR P16473 5/20 0.56
CYP2A6 P11509 3/20 0.56
TDP1 Q9NUW8 2/20 0.56
HPGD P15428 4/20 0.50
CYP1A2 P05177 3/20 0.50
CYP3A4 P08684 1/20 0.50
KEAP1 Q14145 1/20 0.50
HPRT1 P00492 1/20 0.50
KDM4E B2RXH2 2/20 0.48
PTPN1 P18031 1/20 0.48
ALPL P05186 1/20 0.48
GAA P10253 1/20 0.48
MAPK1 P28482 3/20 0.48
L3MBTL1 Q9Y468 3/20 0.48
ATM Q13315 2/20 0.48
NISCH Q9Y2I1 1/20 0.47
POLB P06746 1/20 0.46
HIF1A Q16665 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphine SCHEMBL29018216 1.00 ALDH1A1 (0.56) ALDH1A1HSD17B10TSHRCYP2A6TDP1
Phosphine SCHEMBL1820375 1.00 ALDH1A1 (0.56) ALDH1A1HSD17B10TSHRCYP2A6TDP1
Phosphine SCHEMBL9249650 0.97 ALDH1A1 (0.53) ALDH1A1HSD17B10TSHRCYP2A6TDP1
SCHEMBL25302086 0.97 ALDH1A1 (0.59) ALDH1A1HSD17B10TSHRCYP2A6TDP1
SCHEMBL27953 0.97 ALDH1A1 (0.59) ALDH1A1HSD17B10TSHRCYP2A6TDP1
SCHEMBL29350007 0.97 ALDH1A1 (0.59) ALDH1A1HSD17B10TSHRCYP2A6TDP1
SCHEMBL17836548 0.94 ALDH1A1 (0.56) ALDH1A1HSD17B10TSHRCYP2A6TDP1
Hydrochloric Acid SCHEMBL4268575 0.94 ALDH1A1 (0.56) ALDH1A1HSD17B10TSHRCYP2A6TDP1
Ammonia Solution, Strong SCHEMBL3156160 0.94 ALDH1A1 (0.56) ALDH1A1HSD17B10TSHRCYP2A6TDP1
SCHEMBL6077039 0.94 ALDH1A1 (0.56) ALDH1A1HSD17B10TSHRCYP2A6TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115340572-A Diphosphine ligand containing xanthene skeleton and synthesis and application thereof 南方科技大学 2022-11-15 CN claimed
CN-122080424-A Tetraphenyl ethylene chiral metal cage complex based on chiral Pt metal coordination and preparation method and application thereof 2026-05-26 CN disclosed
CN-117693430-A Compound, rubber blend comprising the compound, vehicle tyre comprising the rubber blend in at least one component, method for producing the compound and use of the compound as an ageing protectant and/or antiozonant and/or dye 大陆轮胎德国有限公司 2024-03-12 CN disclosed
CN-116947925-A Bridged biphenyl monophosphine ligand containing benzofuran structure, and preparation method and application thereof 中山大学 2023-10-27 CN disclosed
CN-115340572-B Biphosphine ligand containing xanthene skeleton and synthesis and application thereof 南方科技大学 2023-05-09 CN disclosed
CN-109438205-B Synthesis method of 2-methyl-2, 3-diaryl propionaldehyde derivative 西北大学 2021-11-12 CN disclosed
EP-1136475-B1 Piperidine and piperazine compounds for use in the treatment of Alzheimer HOFFMANN LA ROCHE (CH) 2004-08-18 EP disclosed
US-6605723-B2 Reacting a protected amino acid ester with a 4-substituted butyric acid derivative, cyclizing the protected intermediate, benzylating and decarboxylating the intermediate, asymmetric hydrogenation using a catalyst HOFFMAN-LA ROCHE INC. 2003-08-12 US disclosed
EP-0751224-B1 PROCESS FOR PRODUCING (R)-2-AMINO-1-PHENYLETHANOL OR HALOGENATED DERIVATIVE THEREOF, PROCESS FOR PRODUCING OPTICALLY ACTIVE PHENYLSERINE OR HALOGENATED DERIVATIVE THEREOF, AND NOVEL COMPOUND 3-(3-CHLOROPHENYL)SERINE DAICEL CHEM (JP) 2003-01-29 EP disclosed
US-20010037026-A1 Process for the preparation of ethanesul fonyl-piperidine derivatives EVOTEC INTERNATIONAL GMBH (DE) 2001-11-01 US disclosed
US-5846792-A Method of producing (R)-2-amino-1-phenylethanol and opticaly active phenylserine and their halogen substituted products using tyrosine decarboxylase DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1998-12-08 US disclosed
US-5731175-A Method of producing (R)-2-amino-1-phenylethanol and optically active phenylserine and their halogen substituted products using microbes DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1998-03-24 US disclosed
EP-0544455-B1 Water-soluble alkali metal sulfonate-substituted binaphthylphosphine transition metal complex and enantioselective hydrogenation method using it TAKASAGO PERFUMERY CO LTD (JP) 1997-02-12 EP disclosed
EP-0751224-A1 PROCESS FOR PRODUCING (R)-2-AMINO-1-PHENYLETHANOL OR HALOGENATED DERIVATIVE THEREOF, PROCESS FOR PRODUCING OPTICALLY ACTIVE PHENYLSERINE OR HALOGENATED DERIVATIVE THEREOF, AND NOVEL COMPOUND 3-(3-CHLOROPHENYL)SERINE DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1997-01-02 EP disclosed
US-5324861-A Selective hydrogenation of olefins, ketones, imines TAKASAGO INTERNATIONAL CORPORATION (JP) 1994-06-28 US disclosed
US-5324861-A Selective hydrogenation of olefins, ketones, imines TAKASAGO INTERNATIONAL CORPORATION (JP) 1994-06-28 US disclosed
US-5274146-A Water-soluble alkali metal sulfonate-substituted binaphthylphosphine transition metal complex and enantioselective hydrogenation method using it TAKASAGO INTERNATIONAL CORPORATION (JP) 1993-12-28 US disclosed
US-5274146-A Water-soluble alkali metal sulfonate-substituted binaphthylphosphine transition metal complex and enantioselective hydrogenation method using it TAKASAGO INTERNATIONAL CORPORATION (JP) 1993-12-28 US disclosed
EP-0544455-A1 Water-soluble alkali metal sulfonate-substituted binaphthylphosphine transition metal complex and enantioselective hydrogenation method using it TAKASAGO INTERNATIONAL CORPORATION (JP) 1993-06-02 EP disclosed
EP-0544455-A1 Water-soluble alkali metal sulfonate-substituted binaphthylphosphine transition metal complex and enantioselective hydrogenation method using it TAKASAGO INTERNATIONAL CORPORATION (JP) 1993-06-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010037026-A1 Process for the preparation of ethanesul fonyl-piperidine derivatives GRIN1, GRIN3A, GRIN2B ALDH1A1 1434/4885HSD17B10 4479/4885TSHR 1354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.